Talk:Roivant Sciences/Archive 1

Archive 1

Possible Edits

I have a COI with the company , but would like to suggest some factual edits/corrections below. Thanks!

1. There is no comma in “Roivant Sciences, Ltd.” it’s just “Roivant Sciences Ltd.” Source: https://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex1011.htm

2. A small grammar correction: It should be “the company’s subsidiaries” not “the companies subsidiaries”

3. There is now a new logo which is on the website and image is here: https://static1.squarespace.com/static/5710e74360b5e95e7434951a/t/58c01b61f7e0abb09ddbdad9/1488984934768/

Also, a lot has changed at the company recently so wanted to include some recent news that might be helpful when editing this page moving forward.

1. Topline data from MINDSET is slated to read out in September. Source: https://www.statnews.com/2017/04/10/axovant-new-ceo-david-hung/

2. Enzyvant developing a therapy for Complete DiGeorge Syndrome. Sources: http://www.dukechronicle.com/article/2017/03/pharmaceutical-company-roivant-sciences-collaborates-with-duke-community-in-drug-research and http://medcitynews.com/2017/04/enzyvant-regenerative-medicine-advanced-therapy-rmat-designation/ and https://endpts.com/ramaswamys-enzyvant-scores-a-double-barreled-fda-commitment-to-help-hustle-a-rare-disease-drug-through-its-bla/

3. Relugolix has generate positive Phase 2 trial data for both uterine fibroids and endometriosis-associated pain. Sources: https://endometriosisnews.com/2017/05/22/myovant-presenta-positive-phase-2-results-relugolix-endometriosis-pain/ and http://www.fiercebiotech.com/biotech/myovant-showcases-positive-relugolix-data-will-pfizer-swoop

4. Dermavant purchased the topical rights to cerdulatinib, a Syk/JAK inhibitor, from Portola Pharmaceuticals. It is also advancing a PDE4 inhibitor in-licensed from Eisai. Source: https://endpts.com/is-biopharmas-midas-man-vivek-ramaswamy-building-a-new-ipo-vehicle-with-dermavant-deal/

Thanks 50.75.206.4 (talk) 20:10, 23 May 2017 (UTC)

Will fix the typos. If the company wants to upload its logo to the commons, the link to do that is here. Make sure who ever does it grants the proper license.

With respect to 1 and 3 - we do not present content about health (like early clinical trial results) based on those kind of sources and we do not care about the timing of release of clinical trial data. This is an encyclopedia not the company's website or some investor board. I will look at items 2 and 4. Jytdog (talk) 20:15, 23 May 2017 (UTC)

Some corrections/additions to consider

I have a COI with the company, but would like to give some factual corrections/additions below. Thank you!

1. Roivant launched a new subsidiary, Urovant, on June 6, 2017. That company is focused on urologic diseases and its initial drug will be developed for overactive bladder (OAB). Sources: http://www.fiercebiotech.com/biotech/roivant-launches-urovant-phase-3-merck-med and http://fortune.com/2017/06/06/biotech-merck-ramaswamy/ and https://endpts.com/ramaswamy-notches-his-5th-biotech-startup-in-3-years-after-inking-a-deal-with-merck-for-phiii-urology-drug/

2. Two errors on Enzyvant bullet: RVT-802 is being developed for “complete DiGeorge Syndrome” (as opposed to standard “DiGeorge Syndrome”), and the treatment involves “thymus tissue,” not "thyroid tissue” as the article current states. Source: http://medcitynews.com/2017/04/enzyvant-regenerative-medicine-advanced-therapy-rmat-designation/?rf=1

3. For Axovant bullet: intepirdine is being developed for Dementia with Lewy Bodies (DLB) in addition to Alzheimer’s disease (minor point, but it is “Alzheimer’s” disease not “Alzheimers” disease). Sources: http://www.wkyc.com/news/health/lewy-body-dementia-second-most-common-form-of-neurodegenerative-dementia-behind-alzheimers/315225308 and http://www.newsobserver.com/news/local/community/chapel-hill-news/article130991774.html The second article also notes that Axovant is also sponsoring Phase 2 trials looking at whether another drug in its pipeline, nelotanserin, can safely and effectively treat visual hallucinations for patients with with Lewy Body Dementia and REM sleep disorders for patients with DLB. Additional source: http://www.fiercebiotech.com/biotech/early-win-means-phase-3-test-way-for-axovant-s-dementia-drug

4. For Myovant bullet: Myovant does not have a “worldwide license” for relugolix, it has a global license *excluding Japan and certain other Asian countries” (those rights are retained by Takeda). Sources: http://www.fiercebiotech.com/biotech/myovant-showcases-positive-relugolix-data-will-pfizer-swoop and https://www.forbes.com/sites/nathanvardi/2016/10/27/the-woman-at-the-center-of-the-biggest-biotech-ipo-of-the-year/#3f2cbff06b08 and http://www.bioworld.com/content/roivants-myovant-sciences-files-173m-ipo-fund-its-phase-iii-ready-asset

5. For Dermavant bullet: Dermavant has three drugs in development, not two. In addition to the two mentioned, there is an oral caspase-1 inhibitor (RVT-201). The available external sources are admittedly not great, but it is inaccurate to state “As of December 2016 it had two drug candidates” since it already had three at that time. Sources: http://adisinsight.springer.com/drugs/800047675 and http://www.biospace.com/News/dermavant-sciences-announces-licensing-of-topical/442576 (under “About Dermavant Sciences”).

6. Roivant’s new logo can be found here:

new Roivant logo

50.75.206.4 (talk) 13:34, 15 June 2017 (UTC)

Wikipedia is not going to be a blow-by-blow update to the various companies' pipelines - that is what their websites are for. I will go back over this and remove some detail so you can stop wasting your time (and ours) with pipeline updates. I fixed the thymus error, thanks for pointing that out. More anon. Jytdog (talk) 13:42, 15 June 2017 (UTC)

 Note: Marked as partial. jd22292 (Jalen D. Folf) (talk) 19:16, 11 July 2017 (UTC)

Additions

I have a COI, but wanted to see if someone could add in two things. Thanks

1. Roivant launched a new subsidiary, Urovant, on June 6, 2017. That company is focused on urologic diseases and its initial drug will be developed for overactive bladder (OAB). Sources: http://www.fiercebiotech.com/biotech/roivant-launches-urovant-phase-3-merck-med http://fortune.com/2017/06/06/biotech-merck-ramaswamy/ https://endpts.com/ramaswamy-notches-his-5th-biotech-startup-in-3-years-after-inking-a-deal-with-merck-for-phiii-urology-drug/ http://www.pharmaceutical-technology.com/news/newsroivant-forms-new-subsidiary-to-develop-urology-therapies-5836970

2. Could we add the CEOs of Roivant’s subsidiaries: Enzyvant: Alvin Shih Source: https://techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Myovant CEO: Lynn Seely Source: https://techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Axovant: David Hung Source: https://www.wsj.com/articles/the-400-million-man-1491838810 Dermavant: Jackie Fouse Source: http://fortune.com/2017/07/10/biotech-celgene-roivant-ceo/

207.38.201.53 (talk) 12:20, 6 August 2017 (UTC)

Did the urovant thing; the CEOs are UNDUE here. 01:38, 7 August 2017 (UTC)

Another addition for consideration:

Could we also add Datavant to the subsidiaries section? Datavant is a new technology-focused subsidiary aimed at using artifical intelligence (AI) to unlock insights in health care datasets. Datavant is the first company in the Roivant family to operate outside of traditional biopharmaceutical development.

Sources: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/?ncid=rss and https://www.wired.com/story/softbank-invests-roivant/ 50.75.206.4 (talk) 16:08, 24 August 2017 (UTC)

Both of those refs talk about plans, not about Datavant actually being created already. Jytdog (talk) 21:04, 24 August 2017 (UTC)

Here is another article that points to the launch of Datavant including its new CEO Travis May. Source: https://endpts.com/tech-maven-travis-may-takes-the-helm-of-roivants-data-mining-startup/ 50.75.206.4 (talk) 15:34, 2 October 2017 (UTC)

Updates

I have a COI with the company but I noticed the article is out of date and wanted to suggest a series of edits to be implemented. Thank you.

1. Roivant licenses more than “late-stage” drug candidates (see Genevant, Axovant gene therapy deals below), so more accurate to say “a company that in-licenses investigational drugs and develops them through subsidiaries.”

2. The company and its affiliates now have offices in:

a. San Francisco, C.A. Source: https://www.xconomy.com/national/2018/01/08/axovant-neuro-drug-stumbles-and-falls-in-phase-2-shares-drop-50/

b. San Diego, C.A. Source: https://www.fiercebiotech.com/biotech/roivant-launches-lung-focused-respivant-phase-2-ipf-drug

c. Irvine, C.A. Source: https://www.fiercebiotech.com/biotech/urovant-poaches-allergan-urology-head-as-new-cmo

d. Brisbane, C.A. Source: http://www.finsmes.com/2017/08/roivant-sciences-raises-1-1-billion-in-equity-funding.html

e. Cambridge, M.A. Source: https://www.forbes.com/sites/matthewherper/2018/07/09/vivek-ramaswamys-enzyvant-asks-fda-to-approve-treatment-for-dying-babies/#6fa8c2211007

f. China (Beijing and Shanghai). Source: https://endpts.com/vivek-ramaswamy-strikes-again-this-time-launching-a-beijing-based-biotech-player-with-a-pipeline/

g. Canada (Vancouver) Source: https://www.biospace.com/article/another-notch-on-the-belt-as-ramaswamy-launches-genevant/

3. New subsidiary launched: Datavant. Aims to “de-silo different data sets across healthcare.” Source: https://endpts.com/what-do-you-get-when-you-integrate-healthcare-data-from-multiple-sources-into-one-comprehensive-global-package-travis-may-says-hes-on-track-to-find-out/

4. New subsidiary launched: Sinovant “aimed at developing innovative treatments for some of China’s most pressing medical concerns.” Launched with a pipeline of 11 investigational biopharmaceutical products for Greater China and other Asian markets, including four therapies suitable for Phase III clinical trial application or registration in China. Source: https://www.biospace.com/article/roivant-launches-new-china-based-startup-sinovant-sciences/

5. New subsidiary launched: Respivant “built around an inhaled drug for treating chronic cough in patients with idiopathic pulmonary fibrosis.” Source: https://www.fiercebiotech.com/biotech/roivant-launches-lung-focused-respivant-phase-2-ipf-drug

6. New subsidiary launched: Genevant “working on a range of RNA-based therapeutics backed by Arbutus’ proprietary lipid nanoparticle and ligand conjugate delivery technologies.” Source: https://endpts.com/vivek-ramaswamy-is-diving-into-rna-launching-a-new-biotech-with-arbutus-and-a-team-of-vets/

7. New subsidiary launched: Metavant a “cardiometabolic disease startup” which holds rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker. Source: https://www.fiercebiotech.com/biotech/roivant-licenses-ligand-diabetes-drug-founds-metavant-as-push-into-cardiometabolic-diseases

8. New subsidiary launched: Immunovant, built around “a fully human monoclonal antibody targeting the neonatal Fc receptor.” Source: https://www.biospace.com/article/roivant-taps-genentech-veteran-as-operating-chair-ahead-of-pipeline-day/

9. New subsidiary launched: Altavant, built around “a possible treatment for pulmonary arterial hypertension and other indications.” Source: https://www.biospace.com/article/big-shakeup-and-restructuring-at-vivek-ramaswamy-s-roivant-companies/

10. After discontinuing intepirdine, Axovant has licensed several investigational gene therapies for Parkinson’s disease, oculopharyngeal muscular dystrophy, and other conditions. Source: https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/; https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/

11. Add “biopharmaceutical” to industry listing as subsidiary companies such as Genevant and Immunovant are operating in that space (i.e. biotech rather than conventional pharmaceutical)

12. Update leadership:

a. Add: Myrtle Potter, Dr. Frank Torti, Adele Gulfo, Sam Azoulay, Ben Zimmer, Allen Waxman. Source: https://endpts.com/genentech-vet-myrtle-potter-takes-a-leading-role-in-vivek-ramaswamys-fast-moving-vant-ops/; https://www.fiercebiotech.com/biotech/roivant-appoints-nea-partner-frank-torti-as-overseer-its-vant-subsidiaries; https://www.fiercebiotech.com/biotech/ex-pfizer-execs-join-roivant-s-c-suite; https://www.biospace.com/article/big-shakeup-and-restructuring-at-vivek-ramaswamy-s-roivant-companies/; https://endpts.com/lundbeck-ceo-bags-20m-bonus-jumping-ship-for-teva-helm/

b. Remove: Dr. Lawrence Friedhoff, William Symonds, Marianne Romeo (employed but not senior leadership and not listed in the cited article)

13. Financing history (if including SoftBank might make sense to list earlier rounds):

a. May 2014 seed round - $93 million lead by QVT Financial, included Dexcel Pharma. Source: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/;

b. December 2015 PE/Growth round - $500 million lead by Viking Global. Source: https://www.forbes.com/sites/nathanvardi/2016/07/13/billionaire-andreas-halvorsens-hedge-fund-backs-private-biotech-roivant-sciences/#5fa85b892455

c. August 2017 PE/Growth round - $1.1 billion lead by Softbank Vision Fund, with participation from Founders Fund. Source: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/

14. In June 2018 Roivant laid off 67 employees, not 70. source: https://www.fiercebiotech.com/roivant-lays-off-staff-reassigns-others-major-reshuffle

15. Add in the logo picture that I’ve uploaded to wiki commons linked here: https://commons.wikimedia.org/wiki/File:Roivant_Logo.png

File:Roivant Logo.png

company logo

— Preceding unsigned comment added by 136.24.120.116 (talk) 22:50, 12 October 2018 (UTC)

Update Requests

I've recently been asked by Roivant Sciences to look over their page and to try to get their recent edit requests implemented. I'm hoping that these requests can be implemented by the many active editors I see on the page and I'm certainly open for any discussions about making this page more accurate and up-to-date. Thank you for any help with this project! FinalFrontier.003 (talk) 10:36, 31 October 2018 (UTC)

Extended content

Current section text: Roivant has operations in the U.S. (Durham, N.C., and New York City), Switzerland, and Bermuda. Proposed section text: Roivant and its subsidiaries have operations in San Francisco, San Diego, Irvine and Brisbane, California; Cambridge, Massachusetts; Durham, North Carolina; Beijing and Shanghai,China and Vancouver, Canada. Current section text: The company's leadership includes Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) and Aciphex (rabeprazole), William Symonds, who led the development of Sovaldi (sofosbuvir), Dr. Mayukh Sukhatme, Matthew Gline, Marianne Romeo and Alan Roemer.[1] Proposed section text: The company's leadership includes Dr. Mayukh Sukhatme, Matthew Gline, Alan Roemer, Myrtle Potter, Dr. Frank Torti, Adele Gulfo, Sam Azoulay, Ben Zimmer and Allen Waxman. Proposed additional text: After this sentence ("On 11th August the company announced that they had raised $1.1 billion equity investment led by the SoftBank Vision Fund.") add this information: In May of 2014 they raised $93 million in a seed round led by QVT Financial which included Dexcel Pharma. In December 2015 they had a PE/Growth round of $500 million led by Viking Global. Then, in August 2017 they had a PE/Growth round of $1.1 billion led by Softbank Vision Fund, with participation from Founders Fund. Proposed additional text: At the end of the article, I'd like to add to the subsidiaries with this information about new subsidiaries: •Datavant is a technology-focused subsidiary aimed at using artificial intelligence (AI) to find insights in health care datasets. Datavant is the first company in the Roivant family to operate outside of traditional biopharmaceutical development. •Sinovant Sciences launched in 2018 to develop treatments for difficult medical issues in China. They started with 11 investigational biopharmaceutical products that will be used for Greater China and other Asian markets. •Respivant Sciences launched in 2018 with an inhaled drug that treats chronic cough in patients who have idiopathic pulmonary fibrosis. •Genevant Sciences was created to work on many RNA-based therapeutics that are backed by Arbutus’ “proprietary lipid nanoparticle and ligand conjugate delivery technologies.” •Metavant is a “cardiometabolic disease startup” which has the rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker. •Immunovant was launched in July 2018 to focus on RVT-1401 and its potential to treat IgG-mediated autoimmune diseases. •Altavant Sciences was launched around RVT-1201 to evaluate the effectiveness of its use as a treatment for pulmonary arterial hypertension. References

Editing

I've recently started to implement some of the changes I outlined above as a stated COI editor. I'd love feedback and discourse to help the page stay current and accurate. Thanks! FinalFrontier.003 (talk) 08:11, 6 November 2018 (UTC)

Edit requests from COI editor

I accidentally made these changes as a COI editor recently and now understand that I need to submit them for review and to have them implemented by all of you. I'd appreciate assistance with these changes and a conversation about what may work and what may not.

Extended content

I'd like this paragraph updated. Reference remains the same. Current text: Urovant was formed in 2017 to complete development of vibegron, a drug candidate for overactive bladder than Merck had developed it through a Phase III trial before deciding to abandon it; Urovant had licensed from Merck. Proposed text: Urovant was formed in 2017 to complete development of vibegron, a drug candidate for overactive bladder that Merck had developed through a Phase III trial before partnering with Kyorin. Urovant later licensed vibegron from Merck. Proposed additional text: At the end of the article, I'd like to add to the subsidiaries with this information about new subsidiaries: •Respivant Sciences launched in 2018 with an inhaled drug that treats chronic cough in patients who have idiopathic pulmonary fibrosis. •Genevant Sciences was created to work on RNA-based therapeutics backed by “proprietary lipid nanoparticle and ligand conjugate delivery technologies.” •Metavant is a “cardiometabolic disease startup” which has the rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker. •Immunovant was launched in July 2018 to focus on RVT-1401 and its potential to treat IgG-mediated autoimmune diseases. •Altavant Sciences was launched around RVT-1201 to evaluate the effectiveness of its use as a treatment for pulmonary arterial hypertension. References

FinalFrontier.003 (talk) 07:43, 14 November 2018 (UTC)

Reply 14-NOV-2018

  Edit request partially implemented  

1. Y The Urovant paragraph was updated.
2. N The proposed additional text was not added, as it contained unattributed quoted material. Quotes must be properly attributed, per MOS:QUOTE.

 Additional changes made:

1. The paragraph concerning Datavent was omitted, as its text was insufficiently paraphrased from the source material. All added text must be placed in an editor's own words and phrasing, per WP:CLOSEPARAPHRASE.
2. The use of they when referring to the company was changed to the company.
3. The use of Dr. when referring to the company's leadership was omitted, per MOS:DOCTOR.
4. Punctuation which followed ref notes was moved to precede ref notes, per MOS:PUNCTREF.

Regards,  Spintendo  12:59, 14 November 2018 (UTC)

Edit requests from COI editor

I’m resubmitting these requests with rewording, being careful not to have unattributed quotes or paraphrased materials from source material. I’ve also asked for a few small wording changes that are new. I appreciate all assistance and feedback on these ideas.

Extended content

There are two places where I’d like just a few words changed: •Current text: Enzyvant was founded to develop therapies for rare diseases. One of its treatments is a version of ceramidase being developed as treatment for Farber disease.[30] Another was licensed from Duke University in 2017 and is a potential treatment for a kind of DiGeorge syndrome… •Proposed text: Enzyvant was founded to develop therapies for rare diseases. One of its treatments is human acid ceramidase being developed as treatment for Farber disease.[30] Another was licensed from Duke University in January 2017 and is a potential treatment for complete DiGeorge Anomaly… •Current text: Myovant has a license in some territories for relugolix. •Proposed text: Myovant has a license outside of Asia for relugolix. Resubmission of text to add to the Wiki article with careful changes so there aren’t unattributed quotes or close paraphrasing. •Respivant Sciences launched in 2018 with an inhaled drug being developed to treat chronic cough for patients who are already diagnosed with idiopathic pulmonary fibrosis. •Genevant Sciences was created to work on RNA-based therapeutics. •Metavant is a startup focusing on cardiometabolic disease. The company has the rights to LGD-6972, a glucagon receptor antagonist, and imeglimin. •Immunovant was launched in July 2018 to focus on the treatment of IgG-mediated autoimmune diseases. •Altavant Sciences was launched to focus on a possible future treatment for pulmonary arterial hypertension. Resubmitting text that was taken out for paraphrasing issues: •Datavant was created to break down silos between healthcare datasets. Datavant is the first of the Roivant subsidiaries that is operating outside of traditional biopharmaceutical development. References

Thanks!FinalFrontier.003 (talk) 07:26, 18 November 2018 (UTC)

Reply to edit request 20-NOV-2018

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  08:05, 20 November 2018 (UTC)

Proposal review 20-NOV-2018

Enzyvant was founded to develop therapies for rare diseases. One of its treatments is human acid ceramidase being developed as treatment for Farber disease. Another was licensed from Duke University in January 2017 and is a potential treatment for complete DiGeorge Anomaly...  Partly approved. Myovant has a license outside of Asia for relugolix.  Clarification needed. Respivant Sciences launched in 2018 with an inhaled drug being developed to treat chronic cough for patients who are already diagnosed with idiopathic pulmonary fibrosis.  Clarification needed. Genevant Sciences was created to work on RNA-based therapeutics.  Approved. Metavant is a startup focusing on cardiometabolic disease. The company has the rights to LGD-6972, a glucagon receptor antagonist, and imeglimin.  Approved. Immunovant was launched in July 2018 to focus on the treatment of IgG-mediated autoimmune diseases.  Partly approved. Altavant Sciences was launched to focus on a possible future treatment for pulmonary arterial hypertension.  Declined. Datavant was created to break down silos between healthcare datasets. Datavant is the first of the Roivant subsidiaries that is operating outside of traditional biopharmaceutical development.  Partly approved. ___________

Edit request: COI editor

I’m requesting a few more edits as a COI editor and I look forward to your feedback.

Extended content

At the end of the intro section, after reference 13, I’m requesting to add • Since its last funding round in August 2017, Roivant has increased its employees from under 350 to 750. During the same timeframe, the number of therapies has increased from 14 to 34. At the end of the Funding section, I’m requesting to add: •In 2018 the company had a PE/Growth round of $200 million that was anchored by four new institutional investors: NovaQuest, RTW, a large US insurance company, and another large US asset manager. At the end of the Axovant line, after reference 21, I’d like to add: •In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica. In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma. At the end of the subsidiary list I’d like to add: •Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases. References

Thank you! FinalFrontier.003 (talk) 04:09, 5 December 2018 (UTC)

Reply to edit request 05-DEC-2018

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  10:55, 5 December 2018 (UTC)

Proposal review 05-DEC-2018

Since its last funding round in August 2017, Roivant has increased its employees from under 350 to 750. During the same timeframe, the number of therapies has increased from 14 to 34.   Clarification needed. In 2018 the company had a PE/Growth round of $200 million that was anchored by four new institutional investors: NovaQuest, RTW, a large US insurance company, and another large US asset manager.  Partly approved. In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica.[3] In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma.   Clarification needed. Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases.   Clarification needed. ___________

Edit request

In my last edit request, I received feedback from @Spintendo: that I needed to find references from outside of the pharmaceutical space. I'm including the sentences I'd like added with the references I've found. Thanks for your help, Spintendo and anyone else who might help me here.

Extended content

At the end of the Axovant line, after reference 21, I’d like to add: •In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica. In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma. At the end of the subsidiary list I’d like to add: •Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases. References

FinalFrontier.003 (talk) 07:12, 16 December 2018 (UTC)

Reply 16-DEC-2018

  Additional references requested  

1. The references from Parkinson's News Today and Muscular Dystrophy News Today are not unconnected to the pharmaceutical industry.
2. The reference labeled BBC World Service is actually a Cincinnati-based NPR affiliate reporting on claims affecting a business, Cincinnati Children’s Hospital Medical Center (CCHMC) which operates in Cincinnati. There exists a connection between the radio station and its listener market on one side and Aruvent on the other, who are subsidiaries of Roivant. Just as local stories in a city have a pull on the reporting resources of a station operating within the same city, this radio station is not independent when it is reporting on a story about a company operating in the same city the radio station operates in.

Please provide secondary sources which are unconnected to either side of the actors involved here — both Roivant / the pharmaceutical industry and CCHMC. Regards,  Spintendo  15:30, 16 December 2018 (UTC)

Offering other sources

Trying again to hit the nail on the head with the type of references requested by @Spintendo:. I'm including the sentences I'd like added with the references I've found. Thanks for your help, Spintendo, and anyone else who might help me here.

Extended content

At the end of the Axovant line, after reference 21, I’d like to add: •In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica. In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma. At the end of the subsidiary list I’d like to add: •Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases. References

FinalFrontier.003 (talk) 10:00, 17 December 2018 (UTC)

Reply 18-DEC-2018

  Edit request implemented  

• Despite the direction to place the first claim "after reference 21", the claim was placed under the same bullet point as other information regarding Axovent, after ref tag number #20.

Regards,  Spintendo  16:13, 18 December 2018 (UTC)

Request to add one subsidiary

I'd like to request that one sentence be added to the list of subsidiaries.

Extended content
Anywhere in the list of sibsidiaries I’d like to add: Altavant Sciences was formed in June 2018 with a therapeutic focus on pulmonary arterial hypertension. References

FinalFrontier.003 (talk) 09:36, 7 January 2019 (UTC)

Reply 07-JAN-2019

   Clarification needed  

• Please clarify what is meant by therapeutic focus, per MOS:IDIOM. As a rule, items which are explainable through brevity may often be clouded by vagueness. Please describe in what way the company focuses on PAH and what it is about that focus that makes the mentioning of its work necessary for the article. This enhanced explanation may help readers who are not familiar with disease states and how companies who treat them describe this attention as a "focusing" of their activities.

Regards,  Spintendo  01:04, 8 January 2019 (UTC)

Notes

I'm resubmitting my request to add one sentence. I've tried to clarify what a "therapeutic focus" means. Thanks!

Extended content
Anywhere in the list of sibsidiaries I’d like to add: Altavant Sciences was formed in June 2018 to develop a new treatment for pulmonary arterial hypertension. References

FinalFrontier.003 (talk) 07:37, 10 January 2019 (UTC)

Reply 10-JAN-2019

  Edit request implemented  

• Thank you for the change in tone for this claim. By using plain-spoken non-industry preferred language, the claim seems more informational as a news item and less like part of a brochure for the company.
• The word new as in "new treatment" was omitted per MOS:RELTIME.

Regards,  Spintendo  11:06, 10 January 2019 (UTC)

Edit request

I'd like to request that one sentence be added to the list of subsidiaries.

Extended content
At the end of the list of sibsidiaries I’d like to add: Alyvant was formed in January 2019 to reduce the cost of commercializing medicines by connecting patient data with physician data. References

Thank you! FinalFrontier.003 (talk) 06:57, 23 January 2019 (UTC)

Reply 23-JAN-2019

   Clarification needed  

• Extraordinary claims require extraordinary references. "Reducing the cost of commercializing medicines" is just such a claim. Please provide references from reliable secondary and third-party sources.

Regards,  Spintendo  07:15, 23 January 2019 (UTC)

@Spintendo: I certainly understand what you are saying, but I would argue that this company exists (as we know) and has a plan (which makes readers understand what their purpose is). I offer a few ideas, but the third idea leaves the reader without a clear understanding of the company's purpose. In terms of references (as we've discussed in the past) it's a biotech company and is being written up in biotech, pharmaceutical and medical publications. These are all the available references at this time.

Extended content
1. Alyvant was formed in January 2019 to connect patient data with physician data with the goal of reducing the cost of commercializing medicines. 2. Alyvant was formed in January 2019 to connnect patients with more suitable medications using technology. 3. Alyvant was formed in January 2019 to connect patient and physician data. References

Thank you for all of your assistance and input, FinalFrontier.003 (talk) 09:13, 23 January 2019 (UTC)

Revised edit request

In response to the feedback I received to my last edit request for Roivant Sciences, I have formulated the sentence I would like added in a new way. This is intended to be added at the end of the list of subsidiaries.

Extended content

Here are three suggestions that I'm making. I'd prefer to have the first sentence used, but I've written sentences 2 and 3 as alternatives depending on what the editor finds most acceptable. I don't have any other references to offer at this time. It's a biotech company and is being written up in biotech, pharmaceutical and medical publications. 1. Alyvant was formed in January 2019 to connect patient data with physician data with the goal of reducing the cost of commercializing medicines. or 2. Alyvant was formed in January 2019 to connnect patients with more suitable medications using technology. or 3. Alyvant was formed in January 2019 to connect patient and physician data. References

Thank you for any assistance you can offer, FinalFrontier.003 (talk) 06:54, 27 January 2019 (UTC)

As the company was only just recently created, any discussion about "what it was formed to do" is to describe a future, hoped-for state of affairs. When a claim is from a company regarding its plans for itself in the future, the claim is not about what was — rather, it discusses what will be — which cannot be done, per WP:NOTACRYSTALBALL. If the company was formed, then that can be mentioned. What the plans are for the company are claims about the future, and cannot be included using Wikipedia's voice. In order to include this claim, the language needs to specify that it is the company itself which is making these claims about its future self (i.e., "Alyvant was formed in January 2019. The company has stated that its goal is to enhance exchanges of information between patients and their physicians" versus "Alyvant was formed in January 2019 to connect patient and physician data."). This improved wording should be referenced by reliable WP:SECONDARY sources unconnected to the company itself.  Spintendo  11:40, 27 January 2019 (UTC)

Notes

References

Edit to intro

I'm requesting a change in the first sentence of the article where it says: Roivant Sciences Ltd. is a pharmaceutical company that in-licenses late-stage drug candidates and develops them through subsidiaries. The wording "late-stage" is not accurate since they have some companies with early stage assets like Axovant, Genevant and Enzyvant (to name a few) and other companies with other focuses in the healthcare space. I'd like to propose that we remove the wording "late-stage" so that the sentence would read "Roivant Sciences Ltd. is a pharmaceutical company that in-licenses drug candidates and develops them through subsidiaries." I can provide other references, if needed, but I think the current ones speak to this change sufficiently. Thank you for any assistance FinalFrontier.003 (talk) 07:13, 13 February 2019 (UTC)

Reply 14-FEB-2019

  Clarification requested  

• When the term late-stage was originally added in 2016, the statement it appeared in was worded as such: "Roivant does this by looking for promising drugs that are not being developed by other biopharmaceutical companies due to financial reasons or commercial alignments, and takes those drugs from where they were left off in late-stage clinical development and brings them through the final stages of approval. Please confirm whether or not this is still the case so that the sentence may either be clarified or omitted. When ready to proceed with the requested information, kindly change the {{request edit}} template's answer parameter to read from |ans=yes to |ans=no. Thank you!
  

Regards,  Spintendo  10:28, 14 February 2019 (UTC)

Thank you for your diligence @Spintendo: The answer to your question is as follows. While the current wording was true at the time, Roivant’s pipeline and business model have expanded significantly since. Their mission is to deliver innovative medicines and technologies to patients and they have moved away from solely late stage clinical development. Notably, they've in-licensed a number of medicines that fall outside of the traditional early stage/late stage drug development paradigm, such as gene therapy assets for Aruvant, Axovant, and Urovant or RNA therapeutic platform for Genevant. Additionally, their subsidiaries Datavant and Alyvant, focused on health data and patient analytics respectively, operate outside of the biopharmaceutical company model. Because of the developments, they believe that there is space for greater clarification in how the statement is currently phrased. I look forward to your reply FinalFrontier.003 (talk) 07:17, 17 February 2019 (UTC)

Thank you for your reply. Based on your answer, the question of what to do here seems simple enough, in that the sentence should be re-worded to state that Roivant originally dealt in "late stage" clinical development, but now operates in an otherwise configuration.  Spintendo  14:18, 18 February 2019 (UTC)

Request edit 20-FEB-2019

In response to my discussion with @Spintendo: I've come up with language that should meet all of the requirements for the first sentence of the article. It currently says "Roivant Sciences Ltd. is a pharmaceutical company that in-licenses late-stage drug candidates and develops them through subsidiaries." I propose that the language be changed to say: Roivant Sciences Ltd. is a biopharmaceutical company that builds subsidiary biotech and health technology companies. The company’s initial strategy was in-licensing late-stage drug candidates but has since expanded its business model to develop earlier stage drug candidates and other healthcare technologies. Thank you for your consideration FinalFrontier.003 (talk) 09:54, 20 February 2019 (UTC)

References

Reply 20-FEB-2019

  Edit request implemented    Spintendo  10:09, 20 February 2019 (UTC)

Thank you for your help @Spintendo:! FinalFrontier.003 (talk) 06:05, 21 February 2019 (UTC)

New edit requests

I have four requests as a COI editor. Thank you.

Extended content

1. Current wording: Axovant Sciences Requested wording: Axovant Gene Therapies Rationale: The name has changed and the wiki should reflect this change. 2. Request: Can we please hyperlink these words: imeglimin, pulmonary arterial hypertension 3. Current wording: The first sentence currently says “Roivant Sciences Ltd. is a pharmaceutical company that builds subsidiary biotech and health technology companies.” Requested wording: “Roivant Sciences Ltd. is a biopharmaceutical company that builds subsidiary biotech and health technology companies.” Rationale: They have a number of biologics and gene therapies in their pipeline, and are moving away from only small-molecule drug development which is typical of pharmaceutical companies. It would be more accurate to define them as a biopharmaceutical company and many references do so. (https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=282015801) 4. Current wording: At the end of the intro it says “In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries.” Requested wording: “In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries. Most of the cuts were in support functions including accounting, human resources, and IT.” Rationale: This wording puts the layoffs and reassignments into context and offers more of an explanation for these changes. References

Thank you FinalFrontier.003 (talk) 07:01, 16 April 2019 (UTC)

Reply 16-APR-2019

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  10:00, 16 April 2019 (UTC)

Proposal review 16-APR-2019

Requested wording: Axovant Gene Therapies  Unable to implement. Can we please hyperlink these words: imeglimin, pulmonary arterial hypertension  Approved. 'Roivant Sciences Ltd. is a biopharmaceutical company that builds subsidiary biotech and health technology companies.' - It would be more accurate to define them as a biopharmaceutical company and many references do so.  Declined. In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries. Most of the cuts were in support functions including accounting, human resources, and IT. Clarification needed. ___________

@Spintendo:: Thank you for your fast attention to my last set of requests. I'd like to clarify why I requested "In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries. Most of the cuts were in support functions including accounting, human resources, and IT.”

Rationale behind request: The restructuring was a significant change to Roivant’s business model. Previously, Roivant supported all of the Vants centrally, including scientific, operations, and back office support for (HR, IT, accounting, etc) as needed. As part of this restructuring (or decentralization as some call it), all business and operating functions were moved to the Vant level and Roivant no longer had to support most of the infrastructure for these groups, leading to a leaner organization overall. Much of this explanation is also offered in this article from fiercebiotech: "Most of the affected employees will find new homes at Roivant’s portfolio of startups. Roivant is set up to provide scientific support and other services to its eight "vant" startups from its own facilities and offices, lessening the need for each business to have its own infrastructure. Pursuing that model, Roivant has expanded in Durham, North Carolina, in recent years, picking up scientists let go by other business that used to have big presences in the region. The changes suggests Roivant is now tweaking that model, reassigning some of its staff to the subsidiaries. Such an administrative change would give leadership teams at each subsidiary more direct control over the people handling their projects."

FinalFrontier.003 (talk) 06:26, 17 April 2019 (UTC) Thanks for your attention to this!

Request to add a sentence

A bit over a week ago I requested to have a sentence added after the sentence that says "In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries.”

• I am requesting to add this sentence “Most of the cuts were in support functions including accounting, human resources, and IT.”

• I was asked to provide more explanation for this additional sentence and the explanation is below. I appreciate having someone evaluate this sentence and add it if they agree it explains the situation better.

Rationale: The restructuring was a significant change to Roivant’s business model. Previously, Roivant supported all of the Vants centrally, including scientific, operations, and back office support for (HR, IT, accounting, etc) as needed. As part of this restructuring (or decentralization as some call it), all business and operating functions were moved to the Vant level and Roivant no longer had to support most of the infrastructure for these groups, leading to a leaner organization overall. Much of this explanation is also offered in this article from fiercebiotech: "Most of the affected employees will find new homes at Roivant’s portfolio of startups. Roivant is set up to provide scientific support and other services to its eight "vant" startups from its own facilities and offices, lessening the need for each business to have its own infrastructure. Pursuing that model, Roivant has expanded in Durham, North Carolina, in recent years, picking up scientists let go by other business that used to have big presences in the region. The changes suggests Roivant is now tweaking that model, reassigning some of its staff to the subsidiaries. Such an administrative change would give leadership teams at each subsidiary more direct control over the people handling their projects."

• Thank you FinalFrontier.003 (talk) 06:58, 25 April 2019 (UTC)

References

Reply 25-APR-2019

• Thank you for providing this clarification. The clarification was not meant for me alone, but was also meant for readers of the article. Businesses around the world on any given day may restructure their operations to certain degrees. This type of routine business event is usually not noteworthy.
• To prevent the article from being weighted down by irrelevant information — and to guard against the company using this information to sculpt a favorable public view about its business operations — the COI editor was asked to clarify for readers of the article what it was about that restructuring which made it noteworthy enough to mention.
• This clarification should be incorporated into the text of the proposal, taking care to be as brief as possible, and to place the references for those explanations at the exact positions in the text where the clarifications are mentioned. Please note that this clarification should not come directly from the company itself (or its press releases) but rather, should be voiced by unconnected sources.

Regards,  Spintendo  11:20, 25 April 2019 (UTC)

Notes

Reply and clarification

Thanks for the clarification, @Spintendo:. I clearly did not understand that this was the request. I'm not sure now if I should make my request below to you or put in an official request. Please let me know if you'd like me to make an official request.

I have two options that I would like to submit.

• 1. I agree, as you stated, that “this type of routine business event is usually not noteworthy.” To that end, I’d like to suggest that we delete this sentence entirely “"In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries.”

• 2. Should this not be the direction editors are willing to take, then I’d like to add these sentences as a clarification to the restructuring:
  • "In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries. Most of the cuts were in support functions including accounting, human resources, and IT as Roivant decentralized its business model, moving business and operating functions to the subsidiary level.

Resubmitting the request

I'm resubmitting a request that I made after the clarifications offered by @Spintendo:.

I'd like to request one of two things:

• 1. Deletion of the sentence "In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries” as this is a routine business event and is not noteworthy.

• 2. Should this not be the direction editors are willing to take, then I’d like to add these sentences as a clarification to the restructuring:
  • "In June 2018, Roivant restructured its business model, laying off 67 employees and reassigning 130 to subsidiaries. Most of the cuts were in support functions including accounting, human resources, and IT as Roivant decentralized its business model, moving business and operating functions to the subsidiary level."

I look forward to getting feedback. Thanks! FinalFrontier.003 (talk) 09:11, 30 April 2019 (UTC)

References

Reply 30-APR-2019

I'm more comfortable mentioning only the layoffs and reassignments and leaving out the phrase "restructuring" which implies a reason for these actions. Also, the phrase concerning "most of the cuts", because the word most runs the risk of garnering a {{By how much}} inline template. The actions themselves should be all that is mentioned: "In June 2018, Roivant laid off 67 employees while reassigning a further 130 employees to subsidiaries." The lead section is not ideal for this information, but as the only other section concerns subsidiaries (and the claim concerns both Roivant and its subsidiaries) there seems to be no other location for it. I'd like to know what other editors suggest. Regards,  Spintendo  15:52, 30 April 2019 (UTC)

Notes

Question about recent reply

Hi @Spintendo:. I really appreciate all of the feedback that you offer and the time that you take to discuss these issues. I notice that there are very few other editors who chime in, however, or ever come to this page so I wanted to ask you what to do about that. You wrote, above, that you'd like to know what other edtiors think, but how can we generate interest in a discussion? Thanks so much FinalFrontier.003 (talk) 06:21, 1 May 2019 (UTC)

@FinalFrontier.003: There's the WikiProject Companies talk page which is well-equipped to handle requests. You might try asking there. We'll leave this request open in the meantime. Regards,  Spintendo  15:57, 1 May 2019 (UTC)

The difficulty I see here is that an expanded explanation on why this restucturing took place may prove illusory. The reasons given before do not delve into levels nearing sufficiency: "As part of this restructuring (or decentralization as some call it), all business and operating functions were moved to the Vant level and Roivant no longer had to support most of the infrastructure for these groups, leading to a leaner organization overall." The part left out in that explanation is evident when one considers what it was, about the company, that made its support for most of the infrastructure for these groups unsustainable.

I don't believe that an answer to this could ever really be sufficiently provided, because it would require a level of frankness for which companies may not be comfortable with or used to expressing. In the end, we would always be left with what the company says are its reasons for doing so — reasons which state what happened (the restructuring) what result was expected to happen (a leaner organization) but not why it happened (in other words, why an action which was previously thought to be sustainable — supporting the Vants in this manner — was later found to be unsustainable).

Just giving the company supplied reason, even when placed in the company's voice and not Wikipedia's, would offer a disservice to the reader because what sounds like an explanation — that they wanted to become a leaner organization — is not really much of an explanation at all, but is really just a goal. Broad based goals are interesting, but not really encyclopedic. What would be more interesting are the specific motivations behind this particular goal being expressed at this particular time, something I don't think is possible or even verifiable. Mentioning what the company says are its reasons for this appears to be a Pandora's box of WP:SPECULATION which might best be left unopened. Regards,  Spintendo  14:43, 2 May 2019 (UTC)

Agree 100 percent with Spintendo that it would leave things open for speculation. It is also not up to Wikipedia to explain why things happened. I would think something like this would suffice - " "In June 2018, Roivant restructured its business model, moving business and operating functions to the subsidiary level, laying off 67 employees and reassigning 130 to subsidiaries.[3]" - This states what happens without the need to explain why. This is also assuming that the references support the statement as I only looked at the proposed wording, not the source. Also, stating "most of the cuts" reads more like something Roviant needs to address outside of Wikipedia. It leaves even more speculation such as "what were the other cuts," "how many were there that weren't support function," "what happened to these people," etc. --CNMall41 (talk) 15:32, 2 May 2019 (UTC)

After a discussion with @Spintendo: and @CNMall41: I'm hoping we can agree on the language submitted here: "In June 2018, Roivant restructured its business model, moving business and operating functions to the subsidiary level, laying off 67 employees and reassigning 130 to subsidiaries."

Thank you FinalFrontier.003 (talk) 06:26, 12 May 2019 (UTC)

References

The standing version is the one agreed upon.  Spintendo  16:20, 16 May 2019 (UTC)

Hi @Spintendo: Can you clarify your recent response to my requested edit when you wrote "The standing version is the one agreed upon" please? The conversation here was only between you and CNMall41 and I wanted to understand if I read something incorrectly in that exchange. CNMall41 wrote "I would think something like this would suffice - 'In June 2018, Roivant restructured its business model, moving business and operating functions to the subsidiary level, laying off 67 employees and reassigning 130 to subsidiaries.'" Given this suggestion, which adds to the overall understanding of what happened with the layoffs and restructuring, I submitted this exact wording in my requested edit. I thought this was a direction that made sense and was being discusssed. Thanks so much FinalFrontier.003 (talk) 06:44, 21 May 2019 (UTC)

One sentence edit request

I'm requesting to have this sentence placed at the very end of the intro after the sentence "In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries."

"In September 2019, Roivant entered into a memorandum of understanding for a $3 billion alliance with Sumitomo Dainippon Pharma."

Thank you, FinalFrontier.003 (talk) 05:20, 8 September 2019 (UTC)

References

Reply 08-SEP-2019

The problem that we have here, is that the Roivant article currently has no main section per se, only Subsidiary and Financial sections which ideally should be subsections of the main section (if there was a main section to be had). In place of this main section, the lead section has become a proxy of sorts for this missing main section. All of the information which should be placed in a main section is being placed in the article's lead section.

Now then, because the lead section is what most readers see first, it appears that a struggle may be taking place where "bad" information (such as layoffs) is requested to be mollified by mitigating "good" information (such as "alliances"). Unfortunately, this newer claim in the proposal contains phrases such as "memorandum of understanding" and "alliance" which is much too vague to be informative. So as it stands, the answer to the request would be   Unable to implement   because it   Needs clarification  . That being said, there are a couple of options available to choose from where everyone might come away happy:

• Option 1: The lead section could be stripped of most of the claims which are present there now, and the stripped information would then form the basis of the missing main section I mentioned earlier. That would solve the problem of the layoffs being mentioned in the lead section (which I suspect is the main reason for today's edit request). This is probably the easiest of the options to fulfill, because it involves only rearrainging information.
• Option 2: The proposed claim could be elaborated upon, where it would be re-scripted to explain in full detail what "understandings" have been reached as well as what form this "alliance" would constitute (I say "would" because at this point the alliance is only being forecasted, and has not occurred yet). This option is probably the most difficult of the options to fulfill, because it would involve deconstructing the company's WP:FLOWERY press-release into something more plain-spoken — a task which would likely prove impossible to reference with WP:SECONDARY sources who are independent of the subject.

I invite the COI editor to choose from the above which course to take, or as an alternative, suggest a third or indeed fourth options which I may have overlooked. Please advise. When ready to proceed with the requested information, kindly change the {{request edit}} template's answer parameter to read from |ans=yes to |ans=no. Thank you!
Regards,  Spintendo  07:38, 8 September 2019 (UTC)

Notes

Reply

Thank you for taking so much time and thought with your answer, @Spintendo:. I definitely think that Option 1 makes sense and that the page is lacking having more subsections. Certainly all of this doesn't need to be in the lead. Many similar pages have a History section, which I believe makes sense to add here. I propose the following material be moved and added to that section:

The company was founded in 2014 by Vivek Ramaswamy. Roivant's initial strategy of in-licensing late-stage drug candidates through subsidiaries was later expanded to develop earlier stage drug candidates and other healthcare technologies through those same subsidiaries. In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries. In September 2019, Roivant entered into a memorandum of understanding for a $3 billion alliance with Sumitomo Dainippon Pharma."

I look forward to your reply FinalFrontier.003 (talk) 05:19, 10 September 2019 (UTC)

References

Reply 10-SEP-2019

  Edit request implemented    Spintendo  06:16, 10 September 2019 (UTC)

Edit Request

As a result of recent news and a final agreement for Roivant, I'm requesting the following text changes. At the end of the susidiaries section, I'm requesting to delete the sentence and references that are currently there and to rewrite it to say:

• Current: In September 2019, Roivant entered into an agreement to sell four of its subsidiaries to Sumitomo Dainippon Pharma: Myovant, Urovant, Enzyvant, and Altavant, for $3 billion dollars. A fifth subsidiary which is part of the deal has yet to be identified.[24][25]
• Proposed replacement sentence: In October 2019, Roivant entered into an agreement to transfer its ownership stakes in five of its subsidiaries to Sumitomo Dainippon Pharma: Myovant, Urovant, Engyvant, Altavant and Spirovant. Sumitomo Dainippon Pharma will also receive a greater than 10% stake in Roivant itself. Roivant will receive $3 billion as an upfront cost for this alliance.

Thank you FinalFrontier.003 (talk) 07:32, 7 November 2019 (UTC)

References

Reply 07-NOV-2019

  Edit request partially implemented  

• Y The claim regarding the "transfer of properties" was implemented.
• N The claim regarding $3 billion in "upfront costs" was not added because it was worded as taking place in the near WP:FUTURE.

Regards,  Spintendo  09:14, 7 November 2019 (UTC)

Reply and additions

Thank you for the assistance with recent edits. I’d like to clean up the page a bit more to reflect these edits and have the following requests.

• 1. Since the $3 billion upfront costs wasn’t added (as it reflected an event from the future), I’d like to propose the following in bold (including a change to the misspelled word Enzyvant): “In October 2019, Roivant announced an agreement to sell five of its subsidiaries, Myovant, Urovant, Enzyvant, Altavant and Spirovant — in addition to a greater than 10% share in itself — to Sumitomo Dainippon Pharma in exchange for a $3 billion upfront payment. “
• 2. I’m requesting to move the Enzyvant sentences currently listed under subsidiaries to be part of the new section of sold subsidiaries (along with Myovant, Urovant and Altavant Sciences) and to reword that bullet which has a note on it that it needs to be clarified.
  • It currently reads as: "Enzyvant was founded to develop therapies for rare diseases.[10][11] One of its treatments is human acid ceramidase, being developed as treatment for Farber disease.[12] Another was licensed from Duke University in 2017 and is a potential treatment for a kind of DiGeorge syndrome; the treatment is thymus tissue that is harvested, treated, and implanted in a person with the condition.[clarify][12]"
  • I'm proposing to reword it to read as: "Enzyvant was founded to develop therapies for rare diseases. The company’s lead therapeutic candidate, RVT-802, is a thymus tissue implantation therapy for the potential treatment of pediatric congenital athymia. Enyzvant completed a biologic licensing application to the FDA for approval of RVT-802 in June 2019. Another potential treatment is human acid ceramidase, being developed for Farber disease."”
• 3. I’d like to add a bullet for Spirovant to the section of sold subsidiaries. I’d like to suggest the following wording: Spirovant, which is focused on developing gene therapies for cystic fibrosis

Thank you FinalFrontier.003 (talk) 08:42, 12 November 2019 (UTC)

References

Reply 12-NOV-2019

  Edit request partially implemented  

1. Y The incorrect spelling of Enzyvant was corrected.
2. N The additional claims regarding Enzyvant were omitted, as that company is no longer a part of the article's subject company. Those claims ought to be moved to the Sumitomo article.
3. Y The language used to describe the Sumitomo transaction was changed from sold to agreed to be sold.
4. Y Spirovant was added to the list of agreed to be sold properties.
5. N The claim regarding the price of the sale to Sumitomo was not added, as the claim describes this as an "upfront payment" without adequately explaining the definition of such a term.

 Additional changes made:

• References which carried the same verifying information (and which in both cases were dated as being published less than 24 hours apart) were consolidated by omitting whichever reference carried the later-published date.
• The list of subsidiaries and the list of agreed to be sold subsidiaries were both placed in alphabetical order.

Regards,  Spintendo  11:28, 12 November 2019 (UTC)

Notes

Tweak request

Thank you for all of the assistance and explanations. I'd like to request the following, with regard to the $3 billion. Can we add the three words in bold here to the sentence: “In October 2019, Roivant agreed to sell five of its subsidiaries, Myovant, Urovant, Enzyvant, Altavant and Spirovant — in addition to a greater than 10% share in itself — to Sumitomo Dainippon Pharma for $3 billion.” FinalFrontier.003 (talk) 08:36, 13 November 2019 (UTC)

 Implemented  Spintendo  11:59, 13 November 2019 (UTC)